Eli Lilly & Co. Gets FDA Approval for New Alzheimer’s Treatment
The news of Eli Lilly & Co. obtaining FDA approval for its new Alzheimer’s treatment has been met with excitement among those in the medical community and loved ones of those affected by the disease.
What Does it Mean?
The approval is significant for Lilly and its investors, as they have been eagerly anticipating this move since the drug showed promising results in clinical trials more than three years ago. The medicine, called Kisunla, is designed to remove toxic amyloid from the brains of patients suffering from early-stage Alzheimer’s.
Comparisons to Leqembi
Eisai Co.’s Leqembi, which was released in the US in 2023, will be the main competitor to Lilly’s drug. While Leqembi’s annual price is slightly lower ($26,500), Kisunla may have a convenience advantage due to its bi-monthly infusions compared to every two weeks for Leqembi. Additionally, doctors may decide to stop treatment if the drug has done its job, which could make its overall cost more manageable for some patients.
Side Effects
Like Leqembi, side effects of Kisunla may include brain swelling or bleeding. A recent study found that brain swelling occurred in 36% of patients who participated in the trial, with 6% showing symptoms. Regular scans will be required to monitor for these effects.
Lower Costs
The total cost of Kisunla treatment could potentially be lower than other amyloid-targeting drugs due to the possibility of discontinuation if the drug is effective in a shorter period. This benefit should be considered when weighing treatment options against the current market leader.
Behind the Scenes
Lilly has faced a series of delays and hurdles in bringing Kisunla to the market. The FDA initially declined early approval due to concerns about data collection and the need for additional analysis. Despite these setbacks, a recent day-long hearing with a panel of experts reviewing the drug’s safety and efficacy helped lead to its eventual approval.
Moving Forward
The approval is an significant victory for those working to combat this debilitating disease. As the market is expected to grow to $13 billion by 2030 from approximately $250 million in 2022, this development could pave the way for further innovation and advancements in the fight against Alzheimer’s.
Conclusion
Lilly’s new Alzheimer’s treatment brings renewed hope to those affected by this debilitating condition and its loved ones. With potential savings, convenience, and promise for future progress, this advancement presents a brighter outlook for those with the condition. As the medical community and drug companies continue to work towards creating innovative solutions, we can expect an enhanced understanding of this complex and complex medical issue.
FAQs
- How much will Kisunla cost?
The initial annual price is estimated to be $32,000. In some cases, the total treatment cost may be lower due to the potential of treatment discontinuation.
- When was Leqembi first available?
Leqembi became available in the US in 2023 and is marketed by Eisai in partnership with Biogen.
- Who are the main competitors in the market?
Besides Eisai’s Leqembi, other competitors include drugs already approved or in development targeting specific areas of the brain.
- Is Kisunla the same type of treatment as Leqembi?
Both Kisunla and Leqembi are infusions targeting the removal of toxic amyloid proteins. They share similar side effect profiles.
- How does Lisuna compare to other Alzheimer’s drugs currently available?
Kisunla belongs to the same class of Alzheimer’s drugs as Leqembi and could be considered a viable treatment option given its potential benefits and competitive price points.
Additional Questions Answered
For more information and queries regarding Kisunla or its rivals, consult with your medical practitioner for personalized guidance.
Author: fortune.com
Orginal Source link